12 mg 与 6 mg 地塞米松对重症 COVID-19 患者血栓栓塞和出血的影响——随机双盲 COVID STEROID 2 试验的事后分析
该研究为 COVID STEROID 2 随机双盲试验的事后分析,纳入瑞典和丹麦 ICU 的 357 例重症 COVID-19 患者,比较每日 12 mg 与 6 mg 地塞米松(最多 10 天)。主要终点为 ICU 期间死亡或血栓栓塞复合结局:12 mg 组 53 例(29%),6 mg 组 53 例(30%),未调整绝对风险差 -0.5%(95%CI -10 至 9.5%,p=1.00),调整 OR 0.93(95%CI 0.58 至 1.49,p=0.77)。次要终点(血栓栓塞、大出血、任何出血)均无确切差异证据。作者结论认为无统计学显著差异,但患者数有限,不确定性仍存。
要点
- 重症 COVID-19 患者每日 12 mg 与 6 mg 地塞米松比较,ICU 期间死亡或血栓栓塞复合结局:12 mg 组 53 例(29%)vs 6 mg 组 53 例(30%),未调整绝对风险差 -0.5%(95%CI -10 至 9.5%,p=1.00)。
- 调整后 OR 0.93(95%CI 0.58 至 1.49,p=0.77),无统计学显著差异。
- 次要终点血栓栓塞、大出血、任何出血均无确切差异证据。
- 作者结论:12 mg 与 6 mg 地塞米松每日给药未导致死亡或血栓栓塞复合结局的统计学显著差异,但患者数有限,不确定性仍存。
适用人群与场景
- 瑞典和丹麦 ICU 中纳入 COVID STEROID 2 试验的重症 COVID-19 患者,共 357 例。
处置流程与药物剂量
- 每日地塞米松 12 mg 与 6 mg 比较,最多 10 天(原文为试验干预方案)。
研究设计与关键结果
- 研究类型:随机双盲 COVID STEROID 2 试验的事后分析;样本量 357 例;人群:瑞典和丹麦 ICU 重症 COVID-19 患者;干预与对照:每日 12 mg vs 6 mg 地塞米松,最多 10 天。
- 主要终点(ICU 期间死亡或血栓栓塞复合结局):12 mg 组 53 例(29%)vs 6 mg 组 53 例(30%),未调整绝对风险差 -0.5%(95%CI -10 至 9.5%,p=1.00),调整 OR 0.93(95%CI 0.58 至 1.49,p=0.77)。
- 次要终点(血栓栓塞、大出血、任何出血):均无确切差异证据。
证据类型、等级与局限
- 证据类型:随机双盲试验的事后分析。
- 局限:原文报告患者数有限,不确定性仍存。
对床旁实践的改变
- 作者认为,在重症 COVID-19 患者中,每日 12 mg 与 6 mg 地塞米松相比未导致死亡或血栓栓塞复合结局的统计学显著差异,但患者数有限,不确定性仍存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Thromboembolism is more common in patients with critical COVID-19 than in other critically ill patients, and inflammation has been proposed as a possible mechanism. The aim of this study was to investigate if 12 mg vs. 6 mg dexamethasone daily reduced the composite outcome of death or thromboembolism in patients with critical COVID-19.
METHODS: Using additional data on thromboembolism and bleeding we did a post hoc analysis of Swedish and Danish intensive care unit patients enrolled in the blinded randomized COVID STEROID 2 trial comparing 12 mg vs. 6 mg dexamethasone daily for up to 10 days. The primary outcome was a composite outcome of death or thromboembolism during intensive care. Secondary outcomes were thromboembolism, major bleeding, and any bleeding during intensive care.
RESULTS: We included 357 patients. Whilst in intensive care, 53 patients (29%) in the 12 mg group and 53 patients (30%) in the 6 mg group met the primary outcome with an unadjusted absolute risk difference of - 0.5% (95% CI - 10 to 9.5%, p = 1.00) and an adjusted OR of 0.93 (CI 95% 0.58 to 1.49, p = 0.77). We found no firm evidence of differences in any of the secondary outcomes.
CONCLUSIONS: Among patients with critical COVID-19, 12 mg vs. 6 mg dexamethasone daily did not result in a statistically significant difference in the composite outcome of death or thromboembolism. However, uncertainty remains due to the limited number of patients.
参考来源
- Jonmarker S, Alarcón F, Litorell J, et al. Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. Ann Intensive Care. 2023. PMID: 36862239. doi:10.1186/s13613-023-01115-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。